Introduction

‘Vasculitis’ is the term used for inflammatory diseases that involve blood vessel walls and the surrounding interstitium. Vasculitis may affect large, medium and small sized arteries, arterioles, capillaries, venules and veins [1]. Only the vasculitides that involve arterioles, capillaries and venules give rise to production of autoantibodies, which can serve as practical surrogate markers of the condition in question. Hence, the primary focus of the present review is on autoantibodies that are characteristically found in small vessel vasculitides [2].

The lack of a unified terminology and classification for the various vasculitic conditions in the 1980s led to several attempts to set up a clinically applicable nomenclature. The American College of Rheumatology proposed classification criteria for some primary vasculitides and advocated the use of somewhat complicated diagnostic algorithms for establishing a precise diagnosis for each condition [3], but one clinically important vasculitic condition, namely microscopic polyangiitis [4], had been left out. A simplified nomenclature for primary vasculitic conditions, each one defined by their most common clinical, histological and immunological characteristics, was proposed by an ad hoc expert committee in 1994 [1]. This so-called Chapel Hill terminology has been widely accepted because of its simplicity and ease of use in clinical work up and is therefore used in this review.

The antineutrophil cytoplasmatic antibodies (ANCAs) directed at proteinase-3 (PR3) and myeloperoxidase (MPO) were discussed at length at the Chapel Hill Conference. That they are very characteristic markers of systemic Wegener’s granulomatosis (WG), Churg–Strauss syndrome and microscopic polyangiitis (as well as limited forms of these conditions, such as renal-limited necrotizing and crescentic glomerulonephritis; NSA = neutrophil-specific autoantibody; PR3 = proteinase-3; SVV = small vessel vasculitis; WG = Wegener’s granulomatosis).
These findings led to great interest in the practical use of phases of the vasculitic disease [15]. Disease activity, with high levels being found in active patients, the levels of MPO-ANCA were dependent on predominantly directed against MPO [14]. Furthermore, in these [11], and these antibodies were found to be predominately targeted by nonspecific inflammatory infiltrates [7]. Lesions in the kidneys are typically those of focal NCGN without immune deposits [8], sometimes termed pauci-immune NCGN.

Antineutrophil cytoplasmic antibodies
The first description of ANCA came from Australia, where patients suffering from NCGN were found to harbour antibodies that reacted with neutrophilic granulocyte cytoplasm by indirect immunofluorescence (IIF) using ethanol-fixed human leucocytes as substrate [9]. These findings were corroborated by a Dutch–Danish study of patients with WG, most of whom had active systemic disease, including nephritis [10]. The classical granular cytoplasmic ANCA (C-ANCA) pattern [11] was found to be caused by ANCA s directed against PR3 [12], and high titters of C-ANCA were confirmed to be associated with active systemic WG [13]. A majority of patients with pauci-immune NCGN without a diagnosis of WG, however, produced ANCA s that selectively stained the perinuclear area of neutrophils and monocytes (P-ANCA) [11], and these antibodies were found to be predominately directed against MPO [14]. Furthermore, in these patients, the levels of MPO-ANCA were dependent on disease activity, with high levels being found in active phases of the vasculitic disease [15].

These findings led to great interest in the practical use of PR3-ANCA and MPO-ANCA as tools for diagnosing and monitoring patients with SVV, but also gave rise to the elaboration of various methods to demonstrate and quantify these antibodies. It soon became apparent that different methodologies led to very different results, and therefore the First International Workshop on ANCA s was established in Copenhagen in 1988. It was agreed to identify one technique to be recommended for use when sera are screened for ANCA using IIF [16]. Follow-up studies revealed a clearly improved recognition of SVV-associated ANCA s and reproducible classification of the two IIF ANCA patterns, but not improved evaluation of titers [17]. However, PR3-ANCA and MPO-ANCA determination was inconsistent and a European multicenter project – the EC/BCR ANCA assay standardization study, supported by the European Commission – was initiated to achieve better standardization. At the end of this project it was concluded that enzyme-linked immunosorbent assay (ELISA) methods using purified native PR3 and MPO, directly coated onto microwells, had been standardized, and it was confirmed that these methods were useful in differentiating patients with recent onset SVV from those with other systemic inflammatory diseases. They also worked well in patients with a previously established diagnosis of WG, Churg–Strauss syndrome or microscopic polyangiitis [18]. It was a major step forward, and receiver operating curves were used to set cutoff values for the PR3-ANCA and MPO-ANCA ELISAs in order to attain satisfactory differentiation from inflammatory disease control patients [18].

Another important conclusion of this study was that ANCA s that are associated with SVV should only be reported as positive if both the IIF test and the direct ELISA for PR3-ANCA or MPO-ANCA are clearly positive. The importance of this combined ANCA testing approach was widely confirmed subsequently [19]. The background for this is the common presence of IIF-ANCA in many chronic inflammatory diseases (e.g. rheumatoid arthritis, Felty's syndrome, systemic lupus erythematosus, ulcerative colitis, chronic active hepatitis, primary sclerosing cholangitis, systemic HIV infection, active tuberculosis, cystic fibrosis, Sweet's syndrome and subacute bacterial endocarditis, among others) [20,21]. Most of these conditions do not result in diagnostically important production of PR3-ANCA or MPO-ANCA. The autoimmune response to neutrophils in these conditions can be regarded as an over-expanded innate immune response to neutrophils that are constantly being recruited to inflammatory sites, the antibodies probably playing a role in the active removal of neutrophil debris. Multiple neutrophil autoantigens both from the cytosolic, granule and nuclear compartments are targeted by such autoantibodies, which for clinical clarity’s sake should be termed ‘neutrophil-specific autoantibodies’ (NSAs) and not ANCA s [22]. If it is locally preferred to retain the term ANCA for such antibodies, then laboratory reports should clearly state that a positive IIF-ANCA that is
combined with negative MPO-ANCA or PR3-ANCA ELISA results is atypical for a patient with SVV [23].

**Immunoglobulin classes of antineutrophil cytoplasmic antibodies**

Early studies indicated that WG-associated ANCs determined using IIF mainly belonged to the IgG class [24]. IgM class ANCs have been found in some patients with haemorrhagic renopulmonary capillaritis [25], but determination of IgM ANCs has not become routine in most immunology laboratories. IgA class ANCs have been reported in some patients with SV, but these findings are controversial and IgA ANCA testing has never come into use.

**Technical issues in testing for antineutrophil cytoplasmic antibodies**

The basic concept underlying ANCA detection using IIF is to allow autoantibodies to react with conformationally preserved intracellular antigens in all compartments of the neutrophil and monocyte, cells that have many biological and functional properties in common and share similar antigens. To gain access to the interior of the cells and make them stay on the slide, some form of permeabilization and fixation is needed. Ethanol and acetone have very similar permeabilization and fixation properties and have both been used, but ethanol is the recommended reagent for this purpose [16]. The advantage of using wholeuffy coat cells instead of isolated neutrophils is that lymphocytes and eosinophils can be useful as control cells. The former may be used to detect the presence of non-organ-specific autoantibodies that react with nuclei (antinuclear antibodies [ANAs]) or cytoplasm (anticytoplasmic antibodies), and the latter may be used as controls for ANCs because neither lymphocytes nor eosinophils should react in the presence of SVV-associated ANCs.

It is distressing that most clinical slide preparations for IIF ANCA detection are covered by purified neutrophils so that the internal control cells are missing, and accordingly other tests must be conducted to exclude ANAs and anticytoplasmic antibodies. P-ANCs and ANAs are sometimes found in the same serum, but direct comparison of their titers by serum dilution is impossible if lymphocytes are absent. The use of HEp-2 cells for estimating ANA levels, commonly set at a cutoff of 1:160, cannot be compared with ANCA levels, which are judged to be positive at lower dilutions (e.g. a cutoff of 1:20) [26]. This problem has been very prominent in studies of ANCs in patients with systemic lupus erythematosus, who regularly harbour antichromatin antibodies. These are seen as a homogeneous or peripheral staining of neutrophil, lymphocyte and eosinophil nuclei on wholeuffy coat smears [16].

The P-ANCA pattern is the result of IgG antibodies reacting with cationic granule proteins (especially MPO, but also lysozyme, cathepsin G, lactoferrin, elastase and azurocidin) that have redistributed from their site of origin in the granules onto the nucleus by ionic attraction to the anionic nucleus upon ethanol fixation [14]. If cells are simultaneously treated by a cross-linking agent such as formalin before execution of the IIF test, then all antigens will stay in situ and MPO-ANCs give rise to a classical C-ANCA reaction [14]. This technique works well for MPO-ANCAs but not for many other NSAs [26]. No consistent studies have been done to show the impact of formalin fixation of neutrophils on demonstration of various specificities of ANCs and ANAs, but formalin treatment commonly destroys the reactivity of a sizeable number of NSAs with neutrophils [26,27]. NSAs that give rise to atypical C-ANCA and P-ANCA patterns in the standard IIF technique most likely represent a summation of reactivities with multiple neutrophil antigens [23].

**Other methods used to determine antineutrophil cytoplasmic antibodies**

There is clearly an agreement between investigators that IIF levels judged by titration are not paralleled by the levels found with use of ELISA methods. In addition, some sera from well-characterized patients with WG have been shown to have classically positive C-ANCA and persistently negative PR3-ANCA using direct ELISA. It has been hypothesized that the discrepancies may be explained by loss of conformational epitopes on the purified PR3 antigen. However, the fact that similarly purified PR3 is reactive with such sera if binding to the solid phase is mediated by a particular anti-PR3 mouse monoclonal antibody makes it more likely that at least one epitope on the PR3 molecule is hidden upon adsorption to the plastic surface [28]. This modification of the ELISA technique has been named ‘capture’ ELISA. The advantage of this technique for detecting PR3-ANCAs has been an increased nosographic sensitivity in patients with SV, but positive reactions are also detected in cases where the disease relapses and the direct ELISA can become negative [28,29]. Even with the use of optimally expressed recombinant PR3 protein [30], the use of the capture principle appears to confer increased reactivity and allows detection of PR3-ANCA as well as PR3-ANCA complexed to its antigen [31]. Therefore, these observations may result from a shift in autoantibody epitope target, better conformation of the PR3 molecule upon monoclonal antibody presentation, and a widened reactivity by detection of immune complexes of PR3/PR3-ANCA. Recent studies suggest that PR3-ANCAs reacting with the proform of PR3 may reflect disease activity better than those directed at mature PR3 [32].

Another principle is to use conformationally preserved radiolabelled PR3 of a crude neutrophil extract as antigen in a precipitation assay [33], but this has not been used widely.
Other antineutrophil cytoplasmic antibody autoantigens

Apart from the major autoantigens MPO and PR3, which are both located in the azurophilic granules of nonactivated neutrophils and monocytes, there are a few other antigens that can be targeted in SVV. Human leukocyte elastase has been found as a target in some patients [34,36], but at least some of these patients most probably have antibodies to a multitude of neutroph granule antigens as part of a drug-induced syndrome that may present just like a primary SVV or a lupus-like syndrome [34,36]. The importance of discovering such a condition is that withdrawal of the offending drug mostly leads to remission of clinical symptoms and disappearance of the ANCA.

Another rare but important antibody specificity is ANCA directed at bactericidal/permeability-increasing protein, which are common in patients with cystic fibrosis and Pseudomonas infections [37] and in patients with other chronic airway infections [38], both conditions in which a secondary vasculitis may develop. ANCA directed at bactericidal/permeability-increasing protein have also been found in patients with inflammatory bowel disease and primary sclerosing cholangitis, which may reflect an immune response to intestinal bacteria permeating through a leaking intestinal wall. IIF-ANCA may be negative in some of these patients although specific ELISA is positive. These patients must be identified in order to avoid risky treatment with immunosuppressive agents and be treated rationally with antibiotics.

Prognostic use of antineutrophil cytoplasm antibodies

Clinical studies of patients with ANCA-associated SVV have indicated that patients with PR3-ANCA have a slightly different disease phenotype than those who have MPO-ANCA [39]. PR3-ANCA-positive patients tend to have more upper airway, nose and ear disease, and perivascular granulomas in biopsy material, whereas MPO-ANCA-positive patients are older, have more peripheral nerve, lung and kidney involvement (rapidly progressive glomerulonephritis, and fewer granulomas. The mortality of patients with microscopic polyangiitis was clearly higher in patients positive for C-ANCA/PR3-ANCA than in those positive for P-ANCA/MPO-ANCA [40], which may relate to the particular predisposition of the former group to have disease relapses [39]. PR3-ANCA indicate a worse prognosis for kidney function than do MPO-ANCA [40]. It is important to appreciate that patients with microscopic polyangiitis are essentially different from patients with classical polyarteritis nodosa [1,41] as the latter do not produce ANCA, have artery involvement only with no SSV, and can often be treated less vigorously.

Some studies indicated that a disease flare in a PR3-ANCA associated vasculitis patient is preceded by a rise in PR3-ANCA levels [42,43] but this may only be seen in about half of the patients [44]. As stated above, the capture technique may be advantageous for using PR3-ANCA as a predictor of and surrogate marker for a vasculitis flare [29,31,45]. Neither direct nor capture technique for MPO-ANCA quantification have been shown to be superior with regard to nosographic sensitivity and relationship to disease activity in SVV.

Other autoantibodies

Most patients who present with the clinical picture of a haemorrhagic renal pulmonary syndrome (previously called Goodpasture’s syndrome) have ANCA in their serum (about 80%) [46,47], which are sometimes accompanied by anti-glomerular basement membrane (GBM) antibodies [46,48]. The rest of these patients have anti-GBM only and therefore have the classical Goodpasture’s syndrome, and these patients are younger than ANCA-associated SVV patients [46]. Patients who coexpress ANCA and anti-GBM antibodies are older and follow a disease course that is not different from that of ANCA-associated SVV [49]. Anti-GBM antibodies are directed at the noncollagenous \( \alpha_3 \) domain of type IV collagen, which is selectively expressed in the GBM and lung basement membrane. They are quite distinct from coexpressed ANCA because they can be differentially removed from serum by absorption. It is possible that MPO-ANCA may aggravate the vasculitic process in patients with mild anti-GBM disease, as has been shown experimentally in rats [50], but there is no agreement as to whether anti-GBM antibodies or ANCA come first.

For many years it has been known that antiendothelial cell antibodies (AECA) are found in many patients with SVV [51,52]. These are independent from ANCA with regard to antigen recognition [53,54], but they may be implicated in the pathogenesis of ANCA-associated SVV [54]. AECA and ANCA levels often fluctuate in parallel during disease relapses and remissions, and it has been suggested that AECA may even be better predictors of relapses than ANCA [52]. A major drawback is the lack of standardization of AECA assays, which limits their clinical use.

Autoantibodies involved in the pathogenesis of small vessel vasculitis

Many excellent studies and reviews have appeared in the literature on this topic [55–58]. The involvement of the various autoantibodies implicated in the pathogenesis of primary SVV is not dealt with in the present review. The recent advancement of an experimental model closely mimicking human MPO-ANCA associated vasculitis is a major step forward for gaining insight into key pathogenetic mechanisms and for testing new potential therapies [59].

Conclusion

The importance of ANCA and anti-GBM antibodies as tools for diagnosing, prognosticating and monitoring
patients with primary SVV is unique in the field of systemic autoimmune disease. If an early diagnosis of SVV is to be established, a team of medical and laboratory specialists must collaborate with the aim of limiting vital organ damage through rational immunomodulating therapy. Complex interactions between autoantibodies, endothelial cells and inflammatory cells, including neutrophils, are likely to act in concert with immune cells in the pathophysiology of SVV and in the perpetuated production of the autoantibodies that are characteristically found in SVV patients. The efficacy of treatment is often mirrored by a decrease in or disappearance of autoantibodies.

**Competing interests**

None declared.

**References**

1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kalloengen CG, et al.: *Nomenclature of systemic vasculitides: the proposal of an international consensus conference*. *Arthritis Rheum* 1994, 37: 187-192.

2. Jennette JC, Falk RJ: *Antineutrophil cytoplasmic autoantibodies and associated diseases: a review*. *Am J Kidney Dis* 1990, 15:517-529.

3. Hunder GG, Arep WD, Bloch DA, Calabrese LH, Fausi AS, Fries JF, Leavitt RY, Lie JT, Lightfoot RW Jr, Mass AT, et al.: *The American College of Rheumatology 1990 criteria for the classification of vasculitis*. *Introduction*, *Arthritis Rheum* 1990, 33:1065-1067.

4. Savage COS, Winears CG, Evand DJ, Rees AJ, Lockwood CM: *Microscopic polyarteritis: presentation, pathology and prognosis*. *J Med* 1985, 56:467-483.

5. Wik AS: *Clinical use of serological tests for antineutrophil cytoplasmic antibodies. What do the studies say?* *Rheum Dis Clin North Am* 2001, 27:799-813.

6. Reinhold-Keller E, de Groot K, Holl-ulrich K, Art AC, Heller M, Feller AC, Gross WL: *Severe CNS manifestations as the clinical hallmark in generalized Wegener’s granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature*. *Clin Exp Rheumatol* 2001, 19:541-549.

7. Rasmussen N, Elsrin, nose and throat manifestations in CANCA-positive vasculitides. *Ann Intern Med* 1992, 143:401-404.

8. Jennette J, Falk R: *The pathology of vasculitis involving the kidney*. *Am J Kidney Dis* 1994, 24:130-141.

9. Davies D, Moran ME, Nall IF, Ryan JB: *Segmental glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology*. *Br J Med* 1982, 285:606.

10. van der Woude FJ, Rasmussen N, Lobatto S, Wik A, Permin H, van Es LA: *Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis*. *Lancet* 1985, i:425-429.

11. Wik A, van der Woude FJ: *The new ACPA/ANCA nomenclature*. *Neth J Med* 1990, 36:107-108.

12. Niles JL, McCluskey RT, Ahmad MF, Arnaout MA: *Wegener’s granulomatosis autoantigen is a novel neutrophil serine protease*. *Blood* 1989, 74:1899-1903.

13. Tervaert JW, van der Woude FJ, Fausi AS, Ambrus JL, Velosa J, Keane WF, Meijer S, van der Giessen M, van der Hem GK, The TH, et al.: *Association between active Wegener’s granulomatosis and anti-neutrophilic antibodies*. *Arch Intern Med* 1998, 149:2461-2465.

14. Falk RJ, Jennette JC: *Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis*. *N Engl J Med* 1988, 318:1651-1657.

15. Tervaert JW, Goldschmeding R, Elsena JD, Limburg PC, van der Giessen M, Huitsma MG, Kollen MI, Hene RJ, The TH, van der Hem GK, et al.: *Association of autoantibodies to myeloperoxidase with different forms of vasculitis*. *Arthritis Rheum* 1990, 33:1264-1272.

16. Wik A: *Delineation of a standard procedure for indirect immunofluorescence detection of ANCA*. *APMIS* 1989, 97 (suppl 6):12-13.

17. Hagen EC, Andrassy K, Chernok E, Daha MR, Gaskin G, Gross W, Lesavre P, Ludemann J, Pusey CD, Rasmussen N, et al.: *The value of indirect immuno-fluorescence and solid phase techniques for ANCA detection. A report on the first phase of an International cooperative study on the standardization of ANCA assays*. *J Immunol Methods* 1993, 159:11-18.

18. Hagen EC, Daha MR, Hermans J, Andrassy K, Caermok E, Gaskin G, Lesavre P, Ludemann J, Rasmussen N, Sinico RA, Wik A, van der Woude FJ: *The diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies (ANCA) in idiopathic systemic vasculitis: an international collaborative study*. *Kidney Int* 1998, 53:743-753.

19. Choi HK, Liu S, Merkel PA, Colditz GA, Niles JL: *Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on myeloperoxidase antibodies*. *J Rheumatol* 2001, 28:1584-1590.

20. Wik A: *Anti-neutrophil cytoplasmic antibodies in primary small vessel vasculitis*. *Scand J Rheumatol* 1996, 25:65-69.

21. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL: *Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease*. *Ann Intern Med* 1997, 126:868-873.

22. Wik A: *Neutrophil-specific autoantibodies in chronic inflammatory bowel diseases*. *Autoimmun Rev* 2002, 1:97-107.

23. Savage J, Gillis D, Benesov D, Ensaill F, Falk RJ, Hagen EC, Jayne D, Jennette JC, Pasapaliar B, Pollock W, Pusey C, Savage CO, Silvestrini R, van der Woude F, Wieslander J, Wik A: *International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA)*. *Am J Clin Pathol* 1999, 111:507-513.

24. Rasmussen N, Wik A: *Autoimmunity in Wegener’s granulomatosis*. In *Immunology, Autoimmunity and Transplantation in Otolaryngology: Proceedings of the First International Academic Conference in Immunology and Immunopathology as applied to Otolaryngology and Rhinology*. Edited by Veldman JE, McCabe JE, Huizing EH, Mygind N. Utrecht: Kugler Publications; 1985:231-236.

25. Jayne DRW, Jones SJ, Severn A, Shaunak S, Murphy J, Lockwood CM: *Severe pulmonary hemorrhage and systemic vasculitis association with circulating antineutrophil cytoplasmic antibodies of IgM class only*. *Clin Nephrol* 1989, 32:101-106.

26. La Cour BB, Wik A, Heier-Madsen M, Baslund B: *Clinical correlates and substrate specificities of antibodies exhibiting neutrophilic nuclear reactivity. A methodological study*. *J Immunol Meth* 1995, 187:287-295.

27. Brimnes J, Halberg P, Wik A, Heegaard NHH: *Specificities of anti-neutrophil autoantibodies in patients with rheumatoid arthritis (RA)*. *Clin Exp Immunol* 1997, 110:250-256.

28. Segelmark M, Westmark K, Wieslander J: *How and why should we detect ANCA?* *Clin Exp Rheumatol* 2000, 18:629-635.

29. Arranz O, Ara J, Rodriguez R, Quinto L, Font J, Mirapeix E, Darnell A: *Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of antineutrophil cytoplasmic antibodies (ANCA) in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients*. *Clin Nephrol* 2001, 56:295-301.

30. Sun J, Fass DN, Viss MA, Hummel AM, Tang H, Homburger HA, Specks U: *A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide*. *Clin Exp Immunol* 1998, 114:320-326.

31. Sun J, Fass DN, Hudson JA, Viss MA, Wieslander J, Homburger HA, Specks U: *Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunocomplexes*. *J Immunol Methods* 1998, 211:111-123.

32. Russell KA, Fass DN, Specks U: *Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener’s granulomatosis and microscopic polyangiitis*. *Arthritis Rheum* 2001, 44:463-468.

33. Lucena-Fernandes F, Dalpe G, Dagenais P, Richard C, Calvert R, Bore G, Menard HA: *Detection of anti-neutrophil cytoplasmic antibodies by immunoprecipitation*. *Clin Invest Med* 1995, 18:153-162.
34. Choi HK, Merkel PA, Walker AM, Niles JL: Drug-associated anti-neutrophil cytoplasmic antibody-positive vasculitides: prevalence among patients with high titers of antimiylperoxidase antibodies. *Arthritis Rheum* 2000, 43:405-413.
35. Apenberg S, Andressy K, Wörner I, Hänisch GM, Roland J, Morcos M, Ritz E: Antibodies to neutrophil elastase: a study in patients with vasculitis. *Am J Kidney Dis* 1996, 28:178-185.
36. Herlin T, Birkaebaek NH, Wolthers OD, Heegaard NH, Wik A: Anti-neutrophil cytoplasmic autoantibody (ANCA) profiles in propylthiouracil-induced lupus-like manifestations in monogenic gouticls with hyperthyroidism. *Scand J Rheumatol* 2002, 31:46-49.
37. Zhao MH, Jayne DRW, Ardiles LG, Culley F, Hodson ME, Lockwood CM: Autoantibodies against bacterial/permeability-increasing protein in patients with cystic fibrosis. *Q J Med* 1996, 89:259-265.
38. Kobayashi O: Clinical role of autoantibody against bactericidal/permeability-increasing protein in chronic airway infection. *J Infect Chemother* 1998, 4:83-93.
39. Franssen C, Gans R, Kallenberg CGM, Hagelukken C, Hoornje S: Disease spectrum of patients with antimiylperoxidase autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. *J Intern Med* 1996, 244:209-219.
40. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ: Prognostic markers in patients with antimiylperoxidase granulomatosis-associated microscopic polyangiitis and glomerulonephritis. *J Am Soc Nephrol* 1999, 7:23-32.
41. Gueulin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrouss B: Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. *Arthritis Rheum* 1999, 42:421-430.
42. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans P, Kallenberg CGM, Brouwer FJ, Callard P, Amouroux J, Casassus P, Jarrousse B: Microscopic polyangiitis: a study in eighty-five patients. *Arthritis Rheum* 2000, 43:2025-2033.
43. Tervaert JW, Huijtema MG, Heine RJ, Sloter WJ, The TH, van der Hem GK, Kallenberg CG: Wegener's granulomatosis: prevention by treatment based on antimiylperoxidase cytoplasmic antibody levels. *Lancet* 1990, ii:709-711.
44. Jayne DRW, Gaskin G, Pusey CD, Lockwood CM: ANCA and prediction of relapse in systemic vasculitides. *Q J Med* 1998, 88:127-133.
45. van der Geld YM, Limburg PC, Kallenberg CG: Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies. *Clin Exp Immunol* 1999, 118:437-446.
46. Saxena R, Bygren P, Arvastson B, Wieslander J: Circulating autoantibodies as serological marker in the differential diagnosis of pulmonary renal syndrome. *J Intern Med* 1995, 238:143-152.
47. Westman KW, Bygren PG, Eliert I, Wik A, Wieslander J: Rapid screening assay for anti-GBM antibody and ANCA: an important tool for the differential diagnosis of pulmonary renal syndromes. *Nephrol Dial Transplant* 1997, 12:1863-1868.
48. Niles JL, Bottinger EP, Saurina GR, Kelly KJ, Pan G, Collins AB, McClusky RT: The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. *Arch Intern Med* 1996, 156:440-445.
49. Short AK, Esnault VL, Lockwood CM: Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: two coexisting distinct autoantibodies detectable in patients with rapidly progressive glomerulonephritis. *Am J Kidney Dis* 1995, 26:439-445.
50. Heeringa P, Brouwer E, Klok PA, Huijtema MG, van den BJ, Weening JJ, Kallenberg CG: Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. *Am J Pathol* 1996, 149:1695-1706.
51. Savage COS, Pottinger BE, Gaskin G, Lockwood CM, Pusey CD, Pearson JD: Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasmic antibodies. *Clin Exp Immunol* 1991, 85:14-19.
52. Chan TM, Frampton G, Jayne DR, Perry GJ, Lockwood CM, Cameron JS: Clinical significance of anti-endothelial cell anti-